S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

Personalis Stock Price, Forecast & Analysis (NASDAQ:PSNL)

$10.68
+0.22 (+2.10 %)
(As of 11/11/2019 04:00 PM ET)
Today's Range
$10.28
Now: $10.68
$10.76
50-Day Range
$10.07
MA: $12.22
$17.15
52-Week Range
$9.65
Now: $10.68
$31.88
Volume5,320 shs
Average Volume355,310 shs
Market Capitalization$332.46 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSNL
CUSIPN/A
CIKN/A
Phone650-752-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees147
Market Cap$332.46 million
Next Earnings Date11/13/2019 (Confirmed)
OptionableNot Optionable

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.


Personalis (NASDAQ:PSNL) Frequently Asked Questions

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

How were Personalis' earnings last quarter?

Personalis (NASDAQ:PSNL) issued its earnings results on Tuesday, August, 13th. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.58. The company earned $15.80 million during the quarter, compared to analyst estimates of $14.92 million. Personalis's revenue for the quarter was up 79.5% compared to the same quarter last year. View Personalis' Earnings History.

When is Personalis' next earnings date?

Personalis is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Personalis.

How can I listen to Personalis' earnings call?

Personalis will be holding an earnings conference call on Wednesday, November 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Personalis issued on next quarter's earnings?

Personalis issued an update on its FY 2019 earnings guidance on Tuesday, August, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60-62 million, compared to the consensus revenue estimate of $59.07 million.

What price target have analysts set for PSNL?

5 equities research analysts have issued 1-year price targets for Personalis' shares. Their forecasts range from $22.00 to $29.00. On average, they expect Personalis' share price to reach $27.00 in the next year. This suggests a possible upside of 152.8% from the stock's current price. View Analyst Price Targets for Personalis.

What is the consensus analysts' recommendation for Personalis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Personalis.

Has Personalis been receiving favorable news coverage?

Media headlines about PSNL stock have trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Personalis earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Personalis.

Are investors shorting Personalis?

Personalis saw a increase in short interest in October. As of October 15th, there was short interest totalling 867,500 shares, an increase of 7.2% from the September 15th total of 809,600 shares. Based on an average daily volume of 313,700 shares, the short-interest ratio is currently 2.8 days. Approximately 5.3% of the shares of the stock are short sold. View Personalis' Current Options Chain.

Who are some of Personalis' key competitors?

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Alibaba Group (BABA), Home Depot (HD), Raytheon (RTN), Cisco Systems (CSCO), CVS Health (CVS), Honeywell International (HON), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Amgen (AMGN) and Texas Instruments (TXN).

Who are Personalis' key executives?

Personalis' management team includes the folowing people:
  • Mr. John West, Co-Founder, CEO, Pres & Director (Age 62)
  • Prof. Russ B. Altman M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board

When did Personalis IPO?

(PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

When does Personalis' lock-up period expire?

Personalis' lock-up period expires on Tuesday, December 17th. Personalis had issued 7,921,500 shares in its IPO on June 20th. The total size of the offering was $134,665,500 based on an initial share price of $17.00. After the expiration of Personalis' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Personalis' major shareholders?

Personalis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (2.58%), Sumitomo Mitsui Trust Holdings Inc. (2.58%), Emerald Advisers LLC (1.05%), Kornitzer Capital Management Inc. KS (0.90%), Emerald Mutual Fund Advisers Trust (0.82%) and Wellington Shields Capital Management LLC (0.44%). View Institutional Ownership Trends for Personalis.

Which institutional investors are buying Personalis stock?

PSNL stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Gabelli Funds LLC, Wellington Shields Capital Management LLC, Kornitzer Capital Management Inc. KS and Gamco Investors INC. ET AL. View Insider Buying and Selling for Personalis.

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $10.68.

How big of a company is Personalis?

Personalis has a market capitalization of $332.46 million. Personalis employs 147 workers across the globe.View Additional Information About Personalis.

What is Personalis' official website?

The official website for Personalis is http://www.personalis.com/.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]


MarketBeat Community Rating for Personalis (NASDAQ PSNL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  65
MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote "Outperform" if you believe PSNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel